Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Surmodics's operating assets for the quarter that ended in Jun. 2025 was $137.1 Mil. Surmodics's operating liabilities for the quarter that ended in Jun. 2025 was $25.9 Mil. Surmodics's Total Assets for the quarter that ended in Mar. 2025 was $163.2 Mil. Therefore, Surmodics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2025 was 0.68.
Surmodics Scaled Net Operating Assets Related Terms
Surmodics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Surmodics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRDX vs CBLL, OFIX, LAB: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Surmodics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surmodics Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Surmodics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.68 mean?
Surmodics (SRDX) has a Scaled Net Operating Assets of 0.68 as of Jun. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Surmodics and its competitors.
Is Surmodics' Scaled Net Operating Assets too high?
Surmodics' current Scaled Net Operating Assets is 0.68. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Surmodics' Scaled Net Operating Assets compare to CBLL and OFIX?
Surmodics' Scaled Net Operating Assets of 0.68 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Surmodics and its competitors. Surmodics's current Scaled Net Operating Assets is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surmodics stock overvalued right now?
Surmodics (SRDX) has a current Scaled Net Operating Assets of 0.68. The stock's GF Value™ is $32.10, compared to a current price of $42.98 — trading 33.9% above its estimated fair value. The current Scaled Net Operating Assets is 0.68. Surmodics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Surmodics (SRDX), the current Scaled Net Operating Assets is 0.68 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surmodics (SRDX) Overvalued in 2026?
Based on GuruFocus' analysis, Surmodics stock appears to be overvalued.
The current stock price of $42.98 is trading 33.9% above its estimated GF Value™ of $32.10.
Key valuation signals for SRDX:
Scaled Net Operating Assets: 0.68
GF Value™: $32.10 vs. price of $42.98 (33.9% above fair value)
No single metric tells the full story. See the SRDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score
Get the complete analysis for SRDX
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRDX has been successfully added to your 
